Beckman Coulter Genomics
This article was originally published in The Gray Sheet
Executive Summary
Newly formed genomic services division of Beckman Coulter combines the firm's Agencourt Bioscience unit and Cogenics, which was acquired in April for $17 million. Cogenics offers a range of integrated services for DNA and RNA extraction, genotyping and full sequencing services. Agencourt's sequencing platforms include the Roche 454 Genome Sequencer FLX with Titanium, Applied Biosystems SOLiD and Illumina Genome Analyzer II. Beckman bought Agencourt for $100 million in 2005 (1"The Gray Sheet" May 2, 2005, In Brief)
You may also be interested in...
Beckman Coulter bags Agencourt Bioscience
Fullerton, Calif.-based biomedical testing firm says purchase of Agencourt for $100 mil., plus up to $40 mil. of contingent payments through 2007, will give it a sustainable share of the genomic testing market. Agencourt's solid-phase reversible immobilization (SPRI) technology, which isolates and purifies RNA and DNA, is used routinely with Beckman's Biomek automated liquid handling system...
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.